Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop rapid flu cpt code supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

Rapid Flu CPT Code: 87804 QW, Antigen vs Molecular Tests

Rapid flu CPT code explained: 87804 with QW for waived antigen kits, how molecular tests differ, and a checklist to verify before you bill.

Written and maintained by CASRAI Editorial Board

Published · Last updated

On this page

Short answer: Medicare documents list CLIA-waived rapid influenza A and B antigen kits under CPT code 87804 with the QW modifier (for example, 87804QW). A rapid molecular flu assay is a different kind of test, and the Medicare billing article for influenza tests says the QW modifier is reported for any CLIA-waived test performed. Which code applies to a given kit depends on the kit, so a clinic or lab should confirm the code and the waived status before it buys or bills.

General information for clinic and laboratory staff, not medical, coding or legal advice. Payer rules differ; the Medicare sources below are one payer’s published position.

Definition and scope: what a rapid flu test CPT code identifies

A CPT code names the laboratory service that was performed, not the brand of kit. The “rapid flu test CPT code” question therefore has two halves: which code family matches the test method, and whether the test system is CLIA-waived, which decides whether a QW modifier goes on the claim. CPT descriptors are published by the American Medical Association, so this page does not reproduce them; it relies on how CMS documents apply the codes.

In Medicare Transmittal 3902 (Change Request 10321, 3 November 2017), CMS announced newly waived tests and listed, among them, two rapid influenza A and B antigen kits as 87804QW: McKesson Consult Influenza A & B (nasal and nasopharyngeal swabs) and PBM ImmunoCard STAT! Flu A&B (nasal and nasopharyngeal swabs). That document is the clearest primary evidence that 87804 is the code family used for rapid influenza antigen kits.

How it works in practice: antigen versus molecular rapid tests

The CDC’s clinician page on influenza testing methods separates two rapid test types. This comparison uses only figures from that page (checked 1 November 2026).

Feature Rapid influenza diagnostic test (RIDT, antigen) Rapid molecular assay
What it detects Influenza viral antigens Viral nucleic acids
Time to result 10-15 minutes Approximately 15-30 minutes
Sensitivity stated by CDC 50-70% (moderate); 75-80% when a reader device is used 90-95% (high)
CLIA status Some tests are CLIA-waived and approved for any outpatient setting; others need a moderately complex laboratory Some are CLIA-waived for point-of-care use
Code family documented by CMS 87804 (with QW when the kit is waived), per Transmittal 3902 Confirm against your payer’s current code list for the exact kit

CDC also notes that FDA now requires RIDTs to achieve 80% sensitivity. The point for supply and billing staff is that “rapid” covers more than one method, and the method drives the code.

QW and CLIA-waived status

The Medicare Coverage Database article Billing and Coding: Influenza Diagnostic Tests (A54769) states that if a CLIA-waived test is performed, the -QW modifier should be reported for the waived test, and its modifier table defines QW as “CLIA waived test.” Transmittal 3902 explains why: Medicare claims are edited at the CLIA certificate level, so a facility with a certificate of waiver is paid for waived-complexity tests, and the listed new tests must carry QW to be recognized as waived. The same transmittal notes that a handful of waived tests (such as 81002 and 82962) do not need QW; do not assume that exception covers flu tests.

The waived status belongs to the specific test system, not to the word “rapid.” The FDA’s CLIA database lists waived analytes including influenza A/B, influenza A and influenza B, and is the place to check a particular kit. For the wider picture, see the CASRAI guides on CLIA-waived point-of-care testing and the CLIA-waived test definition.

Confirmatory testing and modifier 59

A54769 says that if a rapid antigen test is performed and then confirmed by PCR, the second test may require the -59 modifier. Modifier 59 is defined there as a “distinct procedural service” modifier, to be used only when no more descriptive modifier is available. For a different modifier family that clinics meet on the supply side, see HCPCS modifiers JW and JZ.

Where it matters for labs, clinics and supply decisions: a checklist

This checklist turns the sources above into questions. Every item traces to CDC, the Medicare article A54769 or Transmittal 3902 (sources below).

  1. Test method. Is the kit an antigen test or a molecular assay? CDC gives different time and sensitivity ranges for each.
  2. Waived or not. Is that exact test system on the FDA CLIA database as waived? CDC says only some tests are, and the others require a moderately complex laboratory.
  3. Certificate. Does the site hold a CLIA certificate that matches the test’s complexity? Medicare edits claims at the certificate level.
  4. QW on the claim. If the test is waived, A54769 says report -QW for it.
  5. Reader device. If the kit uses a reader, CDC’s 75-80% figure applies to reader-based RIDTs, not to visual reads.
  6. Confirmatory workflow. If antigen results are followed by PCR, check how your payer treats the second test (A54769: it may need -59).
  7. Documentation. A54769 cites Social Security Act section 1833(e): Medicare does not pay claims that lack the necessary documentation.
  8. Supplier paperwork. Ask the supplier for the package insert or instructions for use and for the kit’s waiver record, so staff can match them to the test system you check in the FDA database. For a broader stocking view, see the urgent care supply checklist and retail clinic supply checklist.

Common misunderstandings

  • “Rapid flu test” means one code. Rapid antigen and rapid molecular tests are different methods, and CDC describes them separately.
  • “Rapid” means waived. CDC says some tests are waived; others require a moderately complex laboratory.
  • QW is optional paperwork. For Medicare, A54769 and Transmittal 3902 tie QW to recognition of the waived test.
  • One payer’s article applies everywhere. A54769 is a Medicare contractor article; commercial and Medicaid payers publish their own rules.

To understand how these kits are built and read, see the CASRAI explainers on point-of-care testing, lateral flow tests and nucleic acid amplification tests.

FAQ

What is the CPT code for a rapid flu test?

For rapid influenza A and B antigen kits that are CLIA-waived, Medicare Transmittal 3902 lists 87804 with the QW modifier (87804QW). Molecular rapid assays are a separate method, so confirm their code for the specific kit with your payer.

Do I add QW to a rapid flu test?

Under the Medicare article A54769, yes when the test performed is CLIA-waived: the -QW modifier should be reported for the waived test.

Can a rapid flu antigen test and a PCR test both be billed?

A54769 says that when a rapid antigen test is confirmed using PCR, the second test may require the -59 modifier. Coverage and edits vary by payer.

How accurate are rapid flu tests?

CDC states 50-70% sensitivity for RIDTs (75-80% with a reader device) and 90-95% for rapid molecular assays, and notes that FDA now requires RIDTs to reach 80% sensitivity.

Sources

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Rapid Flu CPT Code: 87804 QW, Antigen vs Molecular Tests

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →